Cargando…

Metformin exerts multitarget antileukemia activity in JAK2(V617F)-positive myeloproliferative neoplasms

The recurrent gain-of-function JAK2(V617F) mutation confers growth factor-independent proliferation for hematopoietic cells and is a major contributor to the pathogenesis of myeloproliferative neoplasms (MPN). The lack of complete response in most patients treated with the JAK1/2 inhibitor ruxolitin...

Descripción completa

Detalles Bibliográficos
Autores principales:	Machado-Neto, João Agostinho, Fenerich, Bruna Alves, Scopim-Ribeiro, Renata, Eide, Christopher A., Coelho-Silva, Juan Luiz, Dechandt, Carlos Roberto Porto, Fernandes, Jaqueline Cristina, Rodrigues Alves, Ana Paula Nunes, Scheucher, Priscila Santos, Simões, Belinda Pinto, Alberici, Luciane Carla, de Figueiredo Pontes, Lorena Lôbo, Tognon, Cristina E., Druker, Brian J., Rego, Eduardo Magalhães, Traina, Fabiola
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2018
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5833553/ https://www.ncbi.nlm.nih.gov/pubmed/29472557 http://dx.doi.org/10.1038/s41419-017-0256-4

Ejemplares similares

NT157 has antineoplastic effects and inhibits IRS1/2 and STAT3/5 in JAK2(V617F)-positive myeloproliferative neoplasm cells
por: Fenerich, Bruna Alves, et al.
Publicado: (2020)

IRS2 silencing increases apoptosis and potentiates the effects of ruxolitinib in JAK2(V617F)-positive myeloproliferative neoplasms
por: de Melo Campos, Paula, et al.
Publicado: (2016)

Paclitaxel induces Stathmin 1 phosphorylation, microtubule stability and apoptosis in acute lymphoblastic leukemia cells
por: Machado-Neto, João Agostinho, et al.
Publicado: (2017)

Insulin Substrate Receptor (IRS) proteins in normal and malignant hematopoiesis
por: Machado-Neto, João Agostinho, et al.
Publicado: (2018)

Synthesis, Antiplasmodial, and Antileukemia Activity of Dihydroartemisinin–HDAC Inhibitor Hybrids as Multitarget Drugs
por: von Bredow, Lukas, et al.
Publicado: (2022)

Reversine exhibits antineoplastic activity in JAK2(V617F)-positive myeloproliferative neoplasms
por: Lima, Keli, et al.
Publicado: (2019)

Altered distribution and function of NK-cell subsets lead to impaired tumor surveillance in JAK2V617F myeloproliferative neoplasms
por: Fernandes de Oliveira Costa, Amanda, et al.
Publicado: (2022)

Repurposing immunosuppressants for antileukemia therapy
por: Sezaki, Maiko, et al.
Publicado: (2022)

Suppression of multiple anti‐apoptotic BCL2 family proteins recapitulates the effects of JAK2 inhibitors in JAK2V617F driven myeloproliferative neoplasms
por: Takei, Hisashi, et al.
Publicado: (2021)

Reactive oxygen species overload promotes apoptosis in JAK2V617F-positive cell lines()
por: Machado-Neto, João Agostinho, et al.
Publicado: (2016)

Synthesis and Antileukemia Activity Evaluation of Benzophenanthridine Alkaloid Derivatives
por: Tang, Yaling, et al.
Publicado: (2022)

Philadelphia-negative myeloproliferative neoplasms as disorders marked by cytokine modulation
por: Cacemiro, Maira da Costa, et al.
Publicado: (2018)

Erratum on “Philadelphia-negative myeloproliferative neoplasms as disorders marked by cytokine modulation”
por: Cacemiro, Maira da Costa, et al.
Publicado: (2021)

Antileukemia Activity and Mechanism of Platinum(II)-Based Metal Complexes
por: Di Pietro, Maria Letizia, et al.
Publicado: (2022)

Apoptosis deregulation in myeloproliferative neoplasms
por: Tognon, Raquel, et al.
Publicado: (2013)

JAK2 V617F: A Single Mutation in the Myeloproliferative Group of Disorders
por: McLornan, Donal, et al.
Publicado: (2006)

Gender and Vascular Complications in the JAK2 V617F-Positive Myeloproliferative Neoplasms
por: Stein, Brady L., et al.
Publicado: (2011)

Jak2V617F myeloproliferative neoplasm stem cells and interferon-alpha
por: Lane, Steven W., et al.
Publicado: (2013)

Detection of JAK2 V617F mutation increases the diagnosis of myeloproliferative neoplasms
por: ZHANG, SHU-PENG, et al.
Publicado: (2015)

Megakaryocytic morphology in Janus kinase 2 V617F positive myeloproliferative neoplasm
por: Ghai, Shuchi, et al.
Publicado: (2017)

Formulation, antileukemia mechanism, pharmacokinetics, and biodistribution of a novel liposomal emodin
por: Wang, Tiechuang, et al.
Publicado: (2012)

Silylation of Deoxynucleotide Analog Yields an Orally Available Drug with Antileukemia Effects
por: Ureshino, Hiroshi, et al.
Publicado: (2021)

JAK2V617F mRNA metabolism in myeloproliferative neoplasm cell lines
por: Nauroy, P, et al.
Publicado: (2014)

Cardiac hypertrophy associated with myeloproliferative neoplasms in JAK2V617F transgenic mice
por: Shi, Kaiyao, et al.
Publicado: (2014)

The Burden of JAK2V617F Mutated Allele in Turkish Patients With Myeloproliferative Neoplasms
por: Yonal-Hindilerden, Ipek, et al.
Publicado: (2015)

Hematopoietic fitness of JAK2(V617F) myeloproliferative neoplasms is linked to clinical outcome
por: Abu-Zeinah, Ghaith, et al.
Publicado: (2022)

The PIP4K2 inhibitor THZ-P1-2 exhibits antileukemia activity by disruption of mitochondrial homeostasis and autophagy
por: Lima, Keli, et al.
Publicado: (2022)

Clinical and molecular profile of a Brazilian cohort of patients with classical BCR-ABL1-negative myeloproliferative neoplasms
por: Porto-Soares, Moysés Antonio, et al.
Publicado: (2020)

Preclinical Antileukemia Activity of Tramesan: A Newly Identified Bioactive Fungal Metabolite
por: Ricciardi, M. R., et al.
Publicado: (2017)

Modeling the Antileukemia Activity of Ellipticine-Related Compounds: QSAR and Molecular Docking Study
por: Márquez, Edgar, et al.
Publicado: (2019)

The JAK2V617F-bearing vascular niche promotes clonal expansion in myeloproliferative neoplasms
por: Zhan, H, et al.
Publicado: (2018)

Expression of CD markers in JAK2(V617F) positive myeloproliferative neoplasms: Prognostic significance
por: Shahrabi, Saeid, et al.
Publicado: (2018)

Erythrocyte-derived microvesicles induce arterial spasms in JAK2(V617F) myeloproliferative neoplasm
por: Poisson, Johanne, et al.
Publicado: (2020)

JAK2 and Beyond: JAK2V617 Mutational Study of Myeloproliferative Disorders and Haematological Malignancies
por: Syeed, Nidda
Publicado: (2019)

Platelet function studies in myeloproliferative neoplasms patients with Calreticulin or JAK2(V617F) mutation
por: Guy, Alexandre, et al.
Publicado: (2023)

Contributions of bone marrow monocytes/macrophages in myeloproliferative neoplasms with JAK2(V617F) mutation
por: Fan, Wenjuan, et al.
Publicado: (2023)

Clinical Impact of JAK2V617F Allele Burden in Philadelphia-Negative Myeloproliferative Neoplasms
por: Yönal-Hindilerden, İpek, et al.
Publicado: (2023)

Energy Metabolism and Redox State in Brains of Wistar Audiogenic Rats, a Genetic Model of Epilepsy
por: Dechandt, Carlos Roberto Porto, et al.
Publicado: (2019)

Prognostic significance of ASXL1, JAK2V617F mutations and JAK2V617F allele burden in Philadelphia-negative myeloproliferative neoplasms
por: Yonal-Hindilerden, Ipek, et al.
Publicado: (2015)

Anti-Glucosylsphingosine Autoimmunity, JAK2V617F-Dependent Interleukin-1β and JAK2V617F-Independent Cytokines in Myeloproliferative Neoplasms
por: Allain-Maillet, Sophie, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_3erla81e2ftm5vcs7drtlafl62